Histone deacetylase inhibitors: Novel agents in cancer treatment

Clinical Journal of Oncology Nursing

Volumn 17, Issue 1, 2013, Pages 34-40

  Glass, Erica ^a   Viale, Pamela Hallquist ^b  

^a St Agnes Cancer Institute   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEPSIPEPTIDE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; ROMIDEPSIN; VORINOSTAT;

ARTICLE; CUTANEOUS T CELL LYMPHOMA; FOOD AND DRUG ADMINISTRATION; HUMAN; NURSING; NURSING EDUCATION; PERIPHERAL T CELL LYMPHOMA; UNITED STATES;

ANTINEOPLASTIC AGENTS; DEPSIPEPTIDES; EDUCATION, NURSING, CONTINUING; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA, T-CELL, CUTANEOUS; LYMPHOMA, T-CELL, PERIPHERAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84873636026     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/13.CJON.34-40     Document Type: Article

References (30)

1. Bi, G., & Jiang, G. (2006). The molecular mechanism of HDAC inhibitors in anticancer effects. Cellular and Molecular Immunology, 3, 285-290.
2. Blagosklonny, M., Trostel, S., Kayastha, G., Demidenko, Z., Vassilev, L., Romanova, L., Fojo, T. (2005). Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Research, 65, 7386-7392. doi:10.1158/0008-5472.CAN-04-3433
3. Blander, G., & Guarente, L. (2004). The SIR2 family of protein deacetylases. Annual Review of Biochemistry, 73, 417-435. doi:10.1146/annurev.biochem.73.011303.073651
4. Celgene Corporation. (2011). Istodax® (romidepsin) [Prescribing information]. Retrieved from http://www.istodax.com/pdfs/ISTODAX_PackageInsert.pdf
5. Chen, C., Wang, Y., Yang, H., Huang, P., Kulp, S., Yang, C., Chen, C. (2007). Histone deacetylase inhibitors sensitize prostate cancer cells to agents that produce DNA double-strand breaks by targeting Ku70 acetylation. Cancer Research, 67, 5318-5327. doi:10.1158/0008-5472.CAN-06-3996
6. Criscione, V., & Weinstock, M. (2007). Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Archives of Dermatology, 143, 854-859. doi:10.1001/archderm.143.7.854
7. Demierre, M., Gan, S., Jones, J., & Miller, D. (2006). Significant impact of cutaneous T-cell lymphoma on patients' quality of life: Results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer, 107, 2504-2511. doi:10.1002/cncr.22252
8. Deroanne, C., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N.S., Castronovo, V. (2002). Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene, 21, 427-436. doi:10.1038/sj/onc/1205108
9. Dickinson, M., Johnstone, R.W., & Prince, H.M. (2010). Histone deacetylase inhibitors: Potential targets responsible for their anti-cancer effect. Investigational New Drugs, 28(Suppl. 1), S3-S20. doi:10.1007/s10637-010-9596-y
10. Dokmanovic, M., Clark, C., & Marks, P. (2007). Histone deacetylase inhibitors: Overview and perspectives. Molecular Cancer Research, 5, 981-989. doi:10.1158/1541-7786.MCR-07-0324
11. Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Frankel, S. (2007). Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood, 109, 31-39. doi:10.1182/blood-2006-06-025999
12. Federico, M., & Bagella, L. (2011). Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. Journal of Biomedicine and Biotechnology. Retrieved from http://www.hindawi.com/journals/biomed/2011/475641/
13. Ishihama, K., Yamakawa, M., Semba, S., Takeda, H., Kawata, S., Kimura, S., & Kimura, W. (2007). Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. Journal of Clinical Pathology, 60, 1205-1210. doi:10.1136/jcp.2005.029165
14. Johnstone, R. (2002). Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nature Reviews Drug Discovery, 1, 287-299. doi:10.1038/nrd772
15. Laharanne, E., Oumouhou, N., Bonnet, F., Carlotti, M., Gentil, C., Chevret, E., Merlio, J. (2010). Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes. Journal of Investigative Dermatology, 130, 1707-1718. doi:10.1038/jid.2010.8
16. Lane, A., & Chabner, B. (2009). Histone deacetylase inhibitors in cancer therapy. Journal of Clinical Oncology, 27, 5459-5468. doi:10.1200/JCO.2009.22.1291
17. Lansigan, F., & Foss, F. (2010). Current and emerging treatment strategies for cutaneous T-cell lymphoma. Drugs, 70, 273-286. doi:10.2165/11532190-000000000-00000
18. Marks, P., & Xu, W. (2009). Histone deacetylase inhibitors: Potential in cancer therapy. Journal of Cellular Biochemistry, 107, 600-608. doi:10.1002/jcb.22185
19. McCann, S. (2007). Cutaneous T-cell lymphoma: Overview and nursing perspectives. Nursing Clinics of North America, 42, 421-455. doi:10.1016/j.cnur.2007.07.002
20. Merck & Co., Inc. (2011). Zolinza® (vorinostat) [Prescribing information]. Retrieved from http://www.merck.com/product/usa/pi_circulars/z/zolinza/zolinza_pi.pdf
21. Olsen, E., Kim, Y., Kuzel, T., Pacheco, T., Foss, S., Parker, S., Duvic, M. (2007). Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment-refractory cutaneous T-cell lymphoma. Journal of Clinical Oncology, 25, 3109-3115. doi:10.1200/JCO.2006.10.2434
22. Piekarz, R., Frye, R., Prince, H., Kirschbaum, M., Zain, J., Allen, S., Bates, S. (2011). Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood, 117, 5827-5834. doi:10.1182/ blood-2010-10-312603
23. Piekarz, R., Frye, R., Turner, M., Wright, J., Allen, S., Kirschbaum, M., Bates, S. (2009). Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. Journal of Clinical Oncology, 27, 5410-5417. doi:10.1200/JCO.2008.21.6150
24. Pons, D., Florentine, R., van den Elsen, P., Heijmans, B., Quax, P., & Jukema, J. (2009). Epigenetic histone acetylation modifiers in vascular remodeling: New targets for therapy in cardiovascular disease. European Heart Journal, 30, 266-277. doi:10.1093/eurheartj/ehn603
25. Scott, G., Mattie, M., Berger, C., Benz, S., & Benz, C. (2006). Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Research, 66, 1277-1281. doi:10.1158/0008-5472.CAN-05-3632
26. Suzuki, J., Chen, Y., Scott, G., DeVries, S., Chin, K., Benz, C., Hwang, E. (2009). Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clinical Cancer Research, 15, 3163-3171. doi:10.1158/1078-0432.CCR-08-2319
27. Thiagalingam, S., Cheng, K., Lee, H., Mineva, N., Thiagalingam, A., & Ponte, J. (2003). Histone deacetylases: Unique players in shaping the epigenetic histone code. Annals of the New York Academy of Sciences, 983, 84-100. doi:10.1111/j.1749-6632.2003.tb05964.x
28. Watanabe, K., Okamoto, K., & Yonehara, S. (2005). Sensitization of osteosarcoma cells to death receptor-mediated apoptosis by HDAC inhibitors through downregulation of cellular FLIP. Cell Death and Differentiation, 12, 10-18. doi:10.1038/sj.cdd.4401507
29. Weichert, W., Roske, A., Gekeler, V., Beckers, T., Ebert, M., Pross, M., Rocken, C. (2008). Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: A retrospective analysis. Lancet Oncology, 9, 139-148. doi:10.1016/S1470-2045(08)70004-4
30. Willemze, R., Jaffe, E., Burg, G., Cerroni, L., Berti, E., Swerdlow, S.H., Meijer, C. (2005). WHO-EORTC classification for cutaneous lymphomas. Blood, 105, 3768-3785. doi:10.1182/blood-2004-09-3502